In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ESC Council of Cardio-Oncology

History

In 2016 the Task Force for Cancer Treatment Toxicity was established and a Position Paper on this topic was published.

In spring 2017 we had the idea to move forward and founded a group inside the ESC on Cardio-Oncology. Following on from a Task Force meeting in Barcelona, it was decided to officially ask the constitution of an ESC Council of Cardio-Oncology. In August 2018 the General Assembly of the ESC definitively approved the Council of Cardio Oncology (CCO)

Who we are

In the coming years there will probably be a Cardio-Oncology ‘epidemic’ due to either the growing population of cancer survivors, the increasing number of patients aged over 65 who need chronic cancer therapy and the high frequency of cancer therapy induced CVDs in these populations. The main goal of Cardio-Oncology is to reduce the burden of CVDs in oncologic patients allowing them to receive the best antitumor therapy (chemotherapy, targeted molecular therapies, hormone therapy, immunotherapy or radiotherapy) with the lowest rate of side effects and treatment interruptions.

Consequently, the ESC created the Council of Cardio-Oncology in August 2018 as a multidisciplinary constituent body which encourages the prevention, early diagnosis and management of cancer therapy-related cardiovascular diseases.

Our aims are to bring together European & non-European specialists in the field and  specialists from Oncology, Hematology, Radiotherapy and related disciplines to enhance the knowledge and the standard of care for Cardio-Oncology patients. We will work in line with all the ESC Strategic Pillars: Advocacy, Congresses, Research, Membership and Education.

Our vision

Improving the prevention, diagnosis, treatment and management of cancer therapy-related cardiovascular diseases.

Top reasons to join the Council

  • Cardio Oncology is a relatively new subspecialty involving all fields of cardiology from ventricular dysfunction to coronary heart disease to arrhythmic issues to vascular complications. Sooner or later you will find a patient with concomitant cancer and cardiac diseases and you will be requested to know at least the essentials of this condition.
  • Cancer incidence and survivorship has greatly increased, leading to an high prevalence of cancer patient survivors. The same for cardiovascular diseases. The probability to encounter patients with both conditions will become more and more frequent in your practice.
  • The long survivorship after cancer therapy may allow to cardiovascular toxicities often spreading after a long time, more than 10 or 20 years, to reach a clinic presentation. The correct diagnosis and also an active screening and research of these cardiovascular conditions may be a cardiologist task in next years.

 Membership is free.

Join now